Research programme: beta lactamase inhibitors - Merck

Drug Profile

Research programme: beta lactamase inhibitors - Merck

Alternative Names: BLIs - Merck

Latest Information Update: 23 Jan 2015

Price : $50

At a glance

  • Originator Cubist Pharmaceuticals
  • Developer Merck & Co
  • Class Small molecules
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections

Most Recent Events

  • 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co
  • 01 Jan 2014 Preclinical trials in Gram-negative infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top